Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Larimar Therapeutics Inc (LRMR)

Larimar Therapeutics Inc (LRMR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 463,507
  • Shares Outstanding, K 63,800
  • Annual Sales, $ 0 K
  • Annual Income, $ -36,950 K
  • 60-Month Beta 0.95
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.07
Trade LRMR with:

Options Overview Details

View History
  • Implied Volatility 108.03% ( +1.21%)
  • Historical Volatility 78.75%
  • IV Percentile 53%
  • IV Rank 38.08%
  • IV High 280.65% on 02/09/24
  • IV Low 1.89% on 11/14/23
  • Put/Call Vol Ratio 0.08
  • Today's Volume 27
  • Volume Avg (30-Day) 97
  • Put/Call OI Ratio 0.19
  • Today's Open Interest 18,076
  • Open Int (30-Day) 23,250

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.23
  • Number of Estimates 1
  • High Estimate -0.23
  • Low Estimate -0.23
  • Prior Year -0.15
  • Growth Rate Est. (year over year) -53.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.08 +9.18%
on 03/27/24
11.97 -35.42%
on 03/06/24
-3.77 (-32.78%)
since 02/28/24
3-Month
4.09 +89.00%
on 01/17/24
13.68 -43.49%
on 02/15/24
+3.13 (+68.04%)
since 12/28/23
52-Week
2.18 +254.59%
on 11/10/23
13.68 -43.49%
on 02/15/24
+3.33 (+75.68%)
since 03/28/23

Most Recent Stories

More News
Larimar: Q4 Earnings Snapshot

Larimar: Q4 Earnings Snapshot

LRMR : 7.70 (+6.06%)
Wall Street Thinks These 2 Biotech Stocks Could Soar in 2024

These two biotech stocks sport notable 12-month price targets. However, they are also uber-risky.

BIIB : 215.61 (-0.34%)
XBI : 95.52 (+0.64%)
XLK : 208.65 (-0.03%)
OCUL : 9.15 (-1.72%)
LRMR : 7.70 (+6.06%)
Larimar: Q3 Earnings Snapshot

Larimar: Q3 Earnings Snapshot

LRMR : 7.70 (+6.06%)
Larimar: Q2 Earnings Snapshot

Larimar: Q2 Earnings Snapshot

LRMR : 7.70 (+6.06%)
Larimar: Q1 Earnings Snapshot

Larimar: Q1 Earnings Snapshot

LRMR : 7.70 (+6.06%)
Nektar Therapeutics (NKTR) Q1 Earnings & Revenues Beat

Nektar's (NKTR) Q1 loss is narrower than expected while revenues beat estimates.

LLY : 783.92 (+0.74%)
NKTR : 0.9167 (+3.57%)
ITRM : 1.5400 (-3.14%)
LRMR : 7.70 (+6.06%)
Larimar (LRMR) Upgraded to Strong Buy: What Does It Mean for the Stock?

Larimar (LRMR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

LRMR : 7.70 (+6.06%)
Theravance's (TBPH) Q1 Earnings and Revenues Miss Estimates

Thervance's (TBPH) first-quarter 2023 loss wider than expected. Revenues decline year over year and also miss estimates.

TBPH : 8.87 (-1.55%)
ITRM : 1.5400 (-3.14%)
LRMR : 7.70 (+6.06%)
VTRS : 11.81 (-0.17%)
New Strong Buy Stocks for May 9th

SBGI, AQST, PLTK, GTX and LRMR have been added to the Zacks Rank #1 (Strong Buy) List on May 9, 2023

SBGI : 13.39 (+1.52%)
AQST : 4.37 (+6.59%)
GTX : 9.96 (-0.70%)
LRMR : 7.70 (+6.06%)
PLTK : 7.03 (+0.57%)
New Strong Buy Stocks for April 19th

SIGA, RYI, LRMR, VRTV and PLL have been added to the Zacks Rank #1 (Strong Buy) List on April 19, 2023.

PLL : 13.25 (-0.45%)
SIGA : 8.45 (-0.59%)
VRTV : 169.99 (+0.02%)
RYI : 33.67 (+2.31%)
LRMR : 7.70 (+6.06%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Larimar Therapeutics Inc. is a clinical-stage biotechnology company. It is focused on developing treatments for rare diseases. The company's lead product consist CTI-1601, which is in clinical stage. Larimar Therapeutics Inc., formerly known as Zafgen Inc., is based in BALA CYNWYD, Pa.

See More

Key Turning Points

3rd Resistance Point 7.84
2nd Resistance Point 7.65
1st Resistance Point 7.46
Last Price 7.70
1st Support Level 7.08
2nd Support Level 6.89
3rd Support Level 6.70

See More

52-Week High 13.68
Fibonacci 61.8% 9.29
Fibonacci 50% 7.93
Last Price 7.70
Fibonacci 38.2% 6.57
52-Week Low 2.18

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar